Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $152 to $155.
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $152 to $155.